Marie de Bakker

Marie de Bakker

Auto-generated profile, based on publicly available information

Marie de Bakker

British Heart Foundation Centre of Research Excellence, Institute for Neurosciences and Cardiovascular Research (M.d.B., A.J.F.T., T.F., Z.L., N.L.M.), University of Edinburgh, Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Atherosclerosis
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
NTNathalie Timmerman
Nathalie Timmerman
IKIan D. van Koeverden
Ian D. van Koeverden
DKDominique P.V. de Kleijn
Dominique P.V. de Kleijn
GBGert J. de Borst
Gert J. de Borst
HRHester M. Den Ruijter
Hester M. Den Ruijter
The sex- and age-related differences in the composition of iliofemoral atherosclerotic plaques are largely unknown. Therefore, the aim of the current study is to gain insight into plaque composition across strata of age and sex in a large cohort of vascular surgery patients. Peripheral atherosclerotic plaques of patients who underwent iliofemoral endarterectomy (n = 790) were harvested between 2002 and 2014. The plaques were semi-quantitatively analyzed for the presence of lipid cores, calcifications, plaque hemorrhages (PH), collagen, macrophage and smooth muscle cell (SMC) content, and quantitatively for microvessel density. Patients were stratified by age tertiles and sex. Ageing was independently associated with rupture-prone iliofemoral plaque characteristics, such as higher prevalence of plaque calcifications (OR 1.52 (95%CI:1.03-2.24) p = 0.035) and PH (OR 1.46 (95%CI:1.01-2.09) p = 0.042), and lower prevalence of collagen (OR 0.52 (95%CI:0.31-0.86) p = 0.012) and SMCs (OR 0.59 (95%CI:0.39-0.90) p = 0.015). Sex-stratified data showed that men had a higher prevalence of lipid cores (OR 1.62 (95%CI:1.06-2.45) p = 0.025) and PH (OR 1.62 (95%CI:1.16-2.54) p = 0.004) compared to women. These sex-differences attenuated with increasing age, with women showing an age-related increase in calcifications (p = 0.002), PH (p = 0.015) and decrease in macrophages (p = 0.005). In contrast, men only showed a decrease in collagen (p = 0.043). Atherosclerotic iliofemoral plaques derived from men display more rupture-prone characteristics compared to women. Yet, this difference is attenuated with an increase in age, with older women having more rupture-prone characteristics compared to younger women.

27 November 2023 in ESC Heart Failure
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
MJMylène Loncq de Jong
Mylène Loncq de Jong
TPTeun Petersen
Teun Petersen
ILIris de Lange
Iris de Lange
KAK. Martijn Akkerhuis
K. Martijn Akkerhuis
IKIsabella Kardys
Isabella Kardys
Aims: This study aims to provide insight into sex-specific cardiovascular protein profiles and their associations with adverse outcomes, which may contribute to a better understanding of heart failure (HF) pathophysiology and the optimal use of circulating proteins for prognostication in women and men. Methods and results: In 250 stable patients with HF with reduced ejection fraction (HFrEF), we performed trimonthly blood sampling (median follow-up: 26 [17–30] months). We selected all baseline samples and two samples closest to the primary endpoint (PEP; composite of cardiovascular death, heart transplantation, left ventricular assist device implantation, and HF hospitalization) or one sample closest to censoring and applied the Olink Cardiovascular III panel. We used linear regression to study sex-based differences in baseline levels and joint models to study differences in the prognostic value of serially measured proteins. In 66 women and 184 men (mean age of 66 and 67 years, respectively), 21% and 28% reached the PEP, respectively. Mean baseline levels of fatty acid-binding protein 4, secretoglobin family 3A member 2, paraoxonase 3, and trefoil factor 3 were higher in women (Pinteraction: 0.001, 0.007, 0.018, and 0.049, respectively), while matrix metalloproteinase-3, interleukin 1 receptor-like 1, and myoglobin were higher in men (Pinteraction: <0.001, 0.001, and 0.049, respectively), independent of clinical characteristics. No significant differences between sexes were observed in the longitudinal associations of proteins with the PEP. Only peptidoglycan recognition protein 1 showed a suggestive interaction with sex for the primary outcome (Pinteraction = 0.028), without multiple testing correction, and was more strongly associated with adverse outcome in women {hazard ratio [HR] 3.03 [95% confidence interval (CI), 1.42 to 6.68], P = 0.008} compared with men [HR 1.18 (95% CI, 0.84 to 1.66), P = 0.347]. Conclusions: Although multiple cardiovascular-related proteins show sex differences at baseline, temporal associations with the adverse outcome do not differ between women and men with HFrEF.

20 November 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
MVMarion van Vugt
Marion van Vugt
RSRuicong She
Ruicong She
IKIsabella Kardys
Isabella Kardys
TPTeun B. Petersen
Teun B. Petersen
MBMarie de Bakker
Marie de Bakker
ASAmand Schmidt
Amand Schmidt
Background: Heart failure (HF) clustering typically relies on clinical characteristics which may not reflect underlying pathophysiology relevant for personalized medicine. We aimed to identify plasma protein profiles of HF patients with reduced ejection fraction (HFrEF). Methods: Using latent class analysis, we derived clusters based on 1) clinical characteristics, and 2) proteomics (SomaScan) from 379 HFrEF patients (median age 64 years [Q1 56; Q3 72], 73% male). Survival analysis assessed associations with major cardiovascular (CV) events (HF hospitalization, CV death, or advanced therapy), HF hospitalization, CV death, and all-cause mortality. Associations were validated in 511 external patients (median age 72 years [Q1 63; Q3 79], 70% male). We identified differentially expressed proteins and explored whether proteins are targets of developmental or approved drugs. Results: We show that clinical clustering identifies three patient clusters without distinct disease progression. Contrary to this, clustering based on plasma proteomics identifies three patient clusters with clear differences in disease, which are validated in the external cohort. The slowly progressing cluster 1 includes younger patients with fewer comorbidities, while the rapidly progressing cluster 3 consists of older patients with more atrial fibrillation and renal failure, and the hospitalization cluster 2 is intermediate in many characteristics. Medication use is similar across clusters. Relative to cluster 1, patients in cluster 2 have an increased risk of major CV events (HR 2.31, 95%CI 1.23; 4.36) and HF hospitalization (HR 2.30, 95%CI 1.10; 4.78). Patients in cluster 3 experienced increased event rates of major CV events (HR 5.84), HF hospitalization (6.50), CV death (8.58), and all-cause mortality (5.07). Twelve proteins are differentially expressed across the identified clusters, including druggable CD2, GDF-15, ABO, IGFBP-1, IGFBP-2, and RNase1. Conclusions: Proteomics-based clustering identifies three HFrEF clusters associated with distinct outcomes that remain undetected using only clinical characteristics.

19 February 2025 in Clinical Chemistry
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
PWPaul Welsh
Paul Welsh
NSNaveed Sattar
Naveed Sattar
BLBertil Lindahl
Bertil Lindahl
OHOla Hammarsten
Ola Hammarsten
KEKai M Eggers
Kai M Eggers
Background: Emerging evidence suggests that the ratio between cardiac troponin (cTn) I and T may provide information on the risk of adverse outcomes in individuals with cardiovascular disease. Whether the cTn I/T ratio provides prognostic insights in the general population is unknown. Methods: The cTn I/T ratio was calculated in 8855 participants (43% female, median age 56 years) from the Generation Scotland Study where both cTnI and cTnT concentrations were above the limit of blank. Multivariable cause-specific Cox proportional hazard models were used to estimate the associations between cTn I/T ratio and the primary outcome of cardiovascular or non-cardiovascular death. Results: The median cTn I/T ratio was 0.5 (25th–75th percentile, 0.3–0.8) and median follow-up was 11.4 (10.8–12.7) years. Individuals in the highest ratio tertile (≥0.64) were more likely to be male, have a higher body mass index and systolic blood pressure, and a history of cardiovascular disease. Those in the lowest ratio tertile (<0.38) were more likely to be smokers or have diabetes. After adjustment for cardiovascular risk factors, the cTn I/T ratio was positively associated with cardiovascular death (per doubling increase, adjusted hazard ratio [HR] 1.16 [95% CI, 1.05–1.28]), while an inverse association was observed for non-cardiovascular death (HR 0.89 [95% CI, 0.81–0.99]). Conclusions: The cTn I/T ratio is positively associated with cardiovascular death in the general population, while inversely associated with non-cardiovascular death. Future research is needed to unravel underlying mechanisms and determine whether the cTn I/T ratio provides valuable information regarding risk of cardiovascular and non-cardiovascular mortality to guide further management.

16 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
NSNiels Tjeerd Benjamin Scholte
Niels Tjeerd Benjamin Scholte
RORohit M. Oemrawsingh
Rohit M. Oemrawsingh
VUVictor A. Umans
Victor A. Umans
BKBas Kietselaer
Bas Kietselaer
FGFranciscus Gasthuis
Franciscus Gasthuis
Background: We aimed to identify patients with subphenotypes of postacute coronary syndrome (ACS) using repeated measurements of high‐sensitivity cardiac troponin T, N‐terminal pro‐B‐type natriuretic peptide, high‐sensitivity C‐reactive protein, and growth differentiation factor 15 in the year after the index admission, and to investigate their association with long‐term mortality risk. Methods and Results: BIOMArCS (BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome) was an observational study of patients with ACS, who underwent high‐frequency blood sampling for 1 year. Biomarkers were measured in a median of 16 repeated samples per individual. Cluster analysis was performed to identify biomarker‐based subphenotypes in 723 patients without a repeat ACS in the first year. Patients with a repeat ACS (N=36) were considered a separate cluster. Differences in all‐cause death were evaluated using accelerated failure time models (median follow‐up, 9.1 years; 141 deaths). Three biomarker‐based clusters were identified: cluster 1 showed low and stable biomarker concentrations, cluster 2 had elevated concentrations that subsequently decreased, and cluster 3 showed persistently elevated concentrations. The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had a similar and favorable long‐term mortality risk. Cluster 3 had the highest mortality risk. The adjusted survival time ratio was 0.64 (95% CI, 0.44–0.93; P =0.018) compared with cluster 1, and 0.71 (95% CI, 0.39–1.32; P =0.281) compared with patients with a repeat ACS. Conclusions: Patients with subphenotypes of post‐ACS with different all‐cause mortality risks during long‐term follow‐up can be identified on the basis of repeatedly measured cardiovascular biomarkers. Patients with persistently elevated biomarkers have the worst outcomes, regardless of whether they experienced a repeat ACS in the first year.

8 January 2023 in Biomarkers
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
JKJaco Kraan
Jaco Kraan
KAK. Martijn Akkerhuis
K. Martijn Akkerhuis
RORohit Oemrawsingh
Rohit Oemrawsingh
FAFolkert W. Asselbergs
Folkert W. Asselbergs
EBEric Boersma
Eric Boersma
Patients who have experienced an acute coronary syndrome (ACS) are at risk of a recurrent event, but their level of risk varies. Because of their close temporal relationship with vascular injury, l...